Ra Pharmaceuticals racks up $58.5 mln Series B

Cambridge, Massachusetts-based biotech company Ra Pharmaceuticals has closed $58.5 million in Series B funding. RA Capital Management, Novo Ventures and Lightstone Ventures led the round with participation from other investors that included Rock Springs Capital Limulus Venture Partners, New Enterprise Associates, Novartis Venture Fund, Morgenthaler Ventures and Amgen Ventures. In conjunction with the funding, Rajeev Shah of RA Capital and Peter Tuxen Bisgaard of Novo Ventures (US) Inc have been added to Ra Pharma’s board of directors.

Immunocore racks up $320 mln

UK-based biotech company Immunocore Limited has closed $320 million in funding. The investors included Woodford Investment Management, Malin Corporation plc, Eli Lilly and Company and RTW Investments. Credit Suisse served as advisor to Immunocore on the transaction.

136 Views

Consortium to buy biotech company Ambrx

A consortium comprised of Shanghai Fosun Pharmaceutical Group, HOPU Investments, China Everbright Limited‘s healthcare fund and WuXi PharmaTech has agreed to acquire Ambrx Inc. No financial terms were disclosed for the transaction that’s expected to be completed in the second quarter of this year. BMO Capital Markets Corp. is serving as financial advisor on the deal. Based in La Jolla, California, Ambrx is a biotech company.

VC-backed Adaptimmune rolls out IPO

UK and Philadelphia-based biotechnology company Adaptimmune Therapeutics plc has debuted its IPO after pricing its 11.25 million shares at $17 per share. The stock began trading Wednesday on the NASDAQ under the ticker symbol “ADAP.” BofA Merrill Lynch, Cowen and Company and Leerink Partners LLC are serving as the lead underwriters. Adaptimmune’s backers include New Enterprise Associates, OrbiMed Advisors, Wellington Management Company, Fidelity Biosciences, Foresite Capital Management, Ridgeback Capital Management and Rock Springs Capital.

Belgian biotech company seeks to go public in U.S.

Belgian biotech company Galapagos NV has filed for a U.S. IPO. The company plans on listing the stock on the NASDAQ under the ticker symbol “GLPG.” Morgan Stanley, Credit Suisse and Cowen and Company are serving as lead underwriters for the U.S. IPO. The company currently trades its shares on the Euronext Amsterdam and Euronext Brussels under the ticker symbol “GLPG.” Galapagos’ backers include Johnson & Johnson, Van Herk Investments and The Capital Group Companies.

Nabriva Therapeutics inks $120 mln Series B

Biotech company Nabriva Therapeutics AG has closed $120 million in Series B funding. Vivo Capital and OrbiMed led the round with participation from EcoR1 Capital, Boxer Capital of Tavistock Life Sciences, HBM, Phase4 Partners, Wellcome Trust, GLSV and Novartis Venture Fund. In addition to the funding, representatives of Vivo Capital and OrbiMed will join Nabriva’s supervisory board.

Edge Therapeutics racks up about $72.5 mln

Berkeley Heights, New Jersey-based Edge Therapeutics, a biotech company focused on developing therapies for neurological conditions, has secured about $72.5 million in funding from two recent rounds. The company just closed $56 million in a Series C-2 funding round led by Venrock with participation from other investors that included Sofinnova Ventures, Janus Capital Management LLC, New Leaf Venture Partners and BioMed Ventures. The earlier round, which closed in December 2014, raised $16.5 million in Series C-1 funding. The investors for that round were not named. In connection to the Series C-2 round, Dr. Anders Hove of Venrock and Dr. James Healy, a managing partner at Sofinnova Ventures, have been added to Edge Therapeutics’ board of directors.

True North Therapeutics scores $35 mln Series B

San Francisco-based biotech company True North Therapeutics has closed $35 million in Series B funding. OrbiMed led the round with participation from return backers Kleiner Perkins Caufield & Byers, MPM Capital, SR One and Baxter Ventures.

103 Views

Nimbus Therapeutics pulls in $43 mln

Cambridge, Massachusetts-based biotech company Nimbus Therapeutics (formerly known as Nimbus Discovery) has closed $43 million in Series B funding. Pfizer Venture Investments and Lightstone Ventures led the round with participation from the company’s previous backers that included Atlas Venture, SR One, Lilly Ventures and Bill Gates.

VC-backed Cidara Therapeutics files for IPO

San Diego-based biotech company Cidara Therapeutics has filed for a $69 million IPO, according to an SEC filing. The company plans on trading on the NASDAQ under the ticker symbol “CDTX.” Jefferies and Leerink Partners are listed as lead underwriters. Cidara’s backers include 5AM Ventures, Aisling Capital, Frazier Healthcare and InterWest Partners.

Prevtec Microbia scores $4.7 mln

Canadian biotech company Prevtec Microbia has raised $4.7 million in funding. The investors included VVC, Telesystem Ltd, Groupe Jafaco Gestion Inc and Desjardins-Innovatech, S.E.C.

Cidara Therapeutics snags $42 mln Series B

San Diego-based biotech firm Cidara Therapeutics Inc has closed $42 million in Series B funding. The investors in this round were not named; however, the firm’s previous backers include 5AM Ventures, Aisling Capital, Frazier Healthcare and InterWest Partners.

Biotech company ORIG3N scores $3.1 mln

Boston-based biotech company ORIG3N has closed $3.1 million in funding. The investors included Hatteras Venture Partners, Harris & Harris Group, KTB and Mountain Group Capital.

105 Views

VC-backed Ascendis Pharma goes public

Danish biotech firm Ascendis Pharma has raised $108 million for its IPO after pricing its 6 million shares at $18 per share. The stock begins trading Wednesday on the NASDAQ under the ticker symbol “ASND.” BofA Merrill Lynch and Leerink Partners are serving as the lead underwriters. Ascendis Pharma’s backers include Sofinnova Ventures, OrbiMed, Vivo Capital, Venrock, RA Capital Management and Janus Capital Management.

135 Views

Biotech firm RetroSense Therapeutics picks up $6 mln

Ann Arbor, Michigan-based biotech firm RetroSense Therapeutics has received $6 million in a Series A financing. The investors included Nerveda, Blue Water Angels, SDL Ventures, Tech Coast Angels and Michigan Economic Development Corp.

175 Views

Deerfield and Roche lead $10 mln round for AveXis

Dallas-based gene therapy-focused biotech firm AveXis has raised $10 million in funding. Deerfield Management and Roche Venture Fund led the round. In addition to the funding, AveXis has added Jonathan Leff of Deerfield and Carole Nuechterlein of Roche Venture Fund to its board of directors.

PE HUB Community

Join the 12519 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget